Pregnancy, Childbirth & Puerperium

Postpartum thyroiditis: recognition

Clinical Overview and When to Suspect Postpartum Thyroiditis

— Affects roughly 5–10% of postpartum women in the US (higher in iodine-replete populations).

— Up to 25% of women with type 1 diabetes, ~25% with prior PPT, and ~50% of TPO-antibody-positive women in early pregnancy will develop PPT.

— Autoimmune flare after the relative immunosuppression of pregnancy; rebound in TPO/Tg antibody titers causes follicular destruction and release of preformed hormone.

— Distinct from Graves disease: PPT is not mediated by TSH-receptor antibodies and lacks hyperfunction on radioiodine uptake.

— Thyrotoxic phase: 1–6 months postpartum, lasts 2–8 weeks.

— Hypothyroid phase: 3–12 months postpartum, lasts 4–6 months.

— Recovery to euthyroid by 12–18 months in ~80%.

— ~40% present with isolated thyrotoxicosis, ~35% with isolated hypothyroidism.

— New fatigue, palpitations, anxiety, heat intolerance, weight loss, or insomnia in a woman 1–6 months postpartum mislabeled as "postpartum blues" or anxiety.

— Persistent fatigue, cold intolerance, constipation, depression, poor lactation, or hair loss 3–12 months postpartum.

— Goiter that is small, firm, painless, nontender (distinguishes from subacute granulomatous thyroiditis).

— History of type 1 DM, prior PPT, known TPO positivity, or other autoimmune disease.

Board pearl: Any woman within 12 months of delivery presenting with new mood, energy, weight, or menstrual changes deserves a TSH — PPT is the most commonly missed postpartum endocrine diagnosis and is frequently misattributed to postpartum depression.

Definition: Postpartum thyroiditis (PPT) is destructive lymphocytic thyroiditis occurring within 12 months of delivery, miscarriage, or medical abortion in women who were euthyroid during pregnancy.

Epidemiology:

Pathophysiology:

Classic triphasic course (~25% of cases):

When to suspect on Step 3:

Presentation Patterns and Key History

— Palpitations, tremor, anxiety, irritability, heat intolerance, insomnia.

— Unintentional weight loss despite good appetite; fatigue paradoxically common.

— Reduced milk supply; emotional lability often mistaken for postpartum mood disorder.

— Symptoms are usually mild and self-limited; severe thyrotoxicosis suggests Graves disease instead.

— Fatigue, cold intolerance, dry skin, constipation, myalgias, hair loss (telogen effluvium overlaps).

— Depressed mood, poor concentration, "brain fog"; may mimic or coexist with postpartum depression.

— Weight gain, impaired lactation, menstrual irregularity once cycles resume.

— Date of delivery, miscarriage, or termination — must be within 12 months.

— Pre-pregnancy and antenatal thyroid status (PPT requires euthyroid pregnancy).

— Personal/family autoimmune disease: type 1 DM, vitiligo, celiac, Hashimoto, Graves.

— Prior PPT (recurrence rate ~70% in subsequent pregnancies).

— Iodine exposure, amiodarone, lithium, interferon, checkpoint inhibitors.

— Neck pain, fever, viral prodrome (would suggest subacute granulomatous thyroiditis instead).

— Ophthalmopathy, pretibial myxedema, or worsening symptoms over time (favors Graves).

— Breastfeeding status — affects later imaging and treatment choices.

— Screening for postpartum depression with PHQ-9 or Edinburgh scale regardless, since the two often coexist.

Key distinction: PPT thyrotoxicosis is destructive and transient, peaking then resolving; Graves disease persists or worsens and is typically accompanied by ophthalmopathy, diffuse bruit, or pretibial myxedema. Time-course and antibody profile separate them.

Thyrotoxic phase (1–6 months postpartum):

Hypothyroid phase (3–12 months postpartum):

Asymptomatic presentations: Up to one-third are detected only by screening labs in high-risk women.

Key history elements:

Physical Exam Findings and Hemodynamic Assessment

— Thyrotoxic phase: mildly anxious, fine resting tremor, warm moist skin, mild tachycardia.

— Hypothyroid phase: dry skin, periorbital puffiness, delayed relaxation of deep tendon reflexes ("hung-up" ankle jerk), bradycardia.

— Thyrotoxic: HR often 90–110, mild systolic hypertension, widened pulse pressure; severe tachyarrhythmia is unusual and should prompt reconsideration of Graves or other cause.

— Hypothyroid: HR 50s–60s, mild diastolic hypertension, occasional hypothermia.

— Small, diffuse, firm, painless, nontender goiter in ~50% — the hallmark.

— No bruit, no thrill (bruit suggests Graves hyperemia).

— No tenderness (tenderness suggests subacute De Quervain thyroiditis).

— Lid lag can occur with any thyrotoxicosis (sympathetic).

— Proptosis, chemosis, restricted EOM, or optic neuropathy indicate Graves ophthalmopathy — exclude PPT.

— Hyperdynamic precordium and accentuated S1 in thyrotoxic phase.

— Quiet precordium, distant heart sounds, possible pericardial effusion in profound hypothyroidism.

— Brisk reflexes thyrotoxic phase; delayed relaxation hypothyroid phase.

— Diffuse non-scarring hair thinning; overlap with normal postpartum telogen effluvium.

— HR >130, fever, agitation, AF with RVR → consider thyroid storm (rare in PPT).

— Hypothermia, hypotension, altered mentation, hyponatremia → myxedema coma (extremely rare).

Step 3 management: A painless, nontender, firm small goiter without bruit in a woman 2–6 months postpartum with mild thyrotoxic symptoms is PPT until proven otherwise — confirm with TSH/FT4 and defer imaging unless Graves is suspected.

General appearance:

Vital signs:

Thyroid exam:

Eye exam:

Cardiac exam:

Neurologic and skin:

Hemodynamic red flags warranting escalation:

Diagnostic Workup — Initial Labs

— Suppressed TSH (<0.1 mIU/L) with elevated free T4/T3 → thyrotoxic phase or Graves.

— Elevated TSH with low/normal free T4 → hypothyroid phase or chronic Hashimoto.

— Normal TSH does not exclude an early or transitioning phase — recheck in 4–6 weeks if symptoms persist.

— Free T4 and total/free T3.

— In PPT thyrotoxicosis, T4:T3 ratio is high because preformed stored hormone (mostly T4) is released — analogous to other destructive thyroiditides.

— In Graves, T3 production is preferentially upregulated, so the T3:T4 ratio is high.

— TPO antibodies positive in ~60–85% of PPT; high titers in early pregnancy predict PPT.

— Thyroglobulin antibodies often co-positive.

— TSH receptor antibody (TRAb/TSI): order in any postpartum thyrotoxicosis to rule out Graves — negative in PPT, positive in Graves.

— CBC, CMP, glucose; screen type 1 DM patients aggressively given high PPT prevalence.

— Lipid panel and CK if frank hypothyroidism.

— βhCG if any concern for new pregnancy (gestational trophoblastic disease can also cause thyrotoxicosis).

— Pregnancy test before any imaging using radioisotope.

— Thyrotoxic phase: recheck TSH/FT4 every 4–8 weeks to detect transition to hypothyroidism.

— Hypothyroid phase: recheck every 6–8 weeks during treatment titration or observation.

Board pearl: A postpartum woman with suppressed TSH, mildly elevated free T4, negative TRAb, and elevated TPO does not need a radioiodine uptake scan — the diagnosis is PPT clinically and serologically.

First test in any suspected postpartum thyroid disorder: serum TSH.

Confirmatory thyroid panel:

Antibodies:

Adjunctive labs:

Depression screening: PHQ-9 or Edinburgh Postnatal Depression Scale — symptoms overlap substantially with hypothyroid phase.

Timing of repeat testing:

Diagnostic Workup — Advanced or Confirmatory Studies

— Indicated only when distinguishing PPT from Graves is unclear (e.g., ambiguous antibodies, persistent thyrotoxicosis, large goiter, ophthalmopathy).

— PPT pattern: LOW uptake (<5% at 24 h) due to destructive release.

— Graves pattern: diffusely INCREASED uptake with homogeneous tracer distribution.

— Toxic nodule/multinodular goiter: focal/patchy uptake.

— Contraindicated in pregnancy and breastfeeding. Lactating women must stop breastfeeding — duration depends on isotope:

– I-123: pump and discard ~3–4 days.

– I-131: discontinue breastfeeding entirely for that child.

– Tc-99m pertechnetate: ~24–48 hours.

— PPT: hypoechoic, heterogeneous parenchyma with normal or decreased vascularity.

— Graves: markedly increased vascularity ("thyroid inferno") with diffuse enlargement.

— Also evaluates nodules if palpable asymmetry exists.

— Normal in PPT (helpful negative finding).

— Markedly elevated with painful thyroid in subacute granulomatous (De Quervain) thyroiditis.

Key distinction: RAIU is the single best test to separate PPT from Graves when clinical/serologic data are ambiguous — low uptake = destructive (PPT), high uptake = hyperfunctioning (Graves). If patient is lactating, use Doppler ultrasound vascularity instead and time RAIU after weaning if needed.

Radioactive iodine uptake (RAIU) and scan:

Thyroid ultrasound with color Doppler (alternative when nursing or pregnancy precludes radioisotopes):

Erythrocyte sedimentation rate / CRP:

Thyroglobulin: Elevated in destructive thyroiditis but rarely needed clinically.

24-hour urinary iodine: Consider if iodine-induced thyrotoxicosis suspected (recent contrast, amiodarone, kelp supplements).

Fine-needle aspiration: Not routine; reserve for dominant or suspicious nodules.

Risk Stratification and First-Line Management Logic

— Mild/asymptomatic → observation with TSH/FT4 every 4–8 weeks.

— Symptomatic (palpitations, tremor, anxiety) → β-blocker (propranolol or metoprolol).

— Do NOT give methimazole or PTU — there is no hyperfunction; destructive release will not respond and you risk iatrogenic hypothyroidism.

— Avoid iodinated contrast and iodine supplements; check medications (amiodarone, lithium).

— Treat with levothyroxine if any of:

– Symptomatic (fatigue, depression, cognitive complaints).

– TSH >10 mIU/L.

– Breastfeeding (even mild hypothyroidism may impair milk supply).

– Attempting next pregnancy or already pregnant.

— Mild asymptomatic TSH 4.5–10 in a non-breastfeeding, non-conceiving woman → observation acceptable, recheck every 6–8 weeks.

— Continue 6–12 months, then taper and reassess unless trying to conceive or pregnant.

— Confirm permanent hypothyroidism (~20–40% at 5–10 years) before lifelong therapy.

— High TPO titer, more severe hypothyroid phase, multiparity, history of miscarriage, ultrasound hypoechogenicity, smoking.

— Recurrence in ~70% of subsequent pregnancies — screen TSH early postpartum next time.

— Lifetime risk of permanent hypothyroidism justifies annual TSH even after recovery.

Step 3 management: First decision branch in postpartum thyrotoxicosis is destructive vs. hyperfunctioning — if PPT, β-blocker only and serial TSH; reserve methimazole for confirmed Graves disease.

Phase-driven management is the central Step 3 concept — PPT is mostly self-limited and treatment is symptomatic, not antithyroid.

Thyrotoxic phase:

Hypothyroid phase:

Duration of levothyroxine:

Risk stratification for permanent hypothyroidism:

Counseling:

Pharmacotherapy — First-Line Drug Regimens

— Propranolol 10–40 mg PO every 6–8 h, titrate to symptom relief and HR <90.

– Lipid-soluble, crosses placenta and into breast milk — but compatible with breastfeeding at standard doses (low relative infant dose).

– Bonus effect: inhibits peripheral T4→T3 conversion at higher doses.

— Metoprolol tartrate 25–50 mg PO BID — also breastfeeding-compatible, longer-acting options for outpatient adherence.

— Atenolol: higher infant milk concentrations — avoid in lactating women.

— Duration: typically 4–8 weeks, taper as TSH normalizes; do not continue into hypothyroid phase (worsens bradycardia and fatigue).

— Contraindications: severe asthma, decompensated heart failure, high-degree AV block.

— Starting dose 1.6 µg/kg/day if overtly hypothyroid; lower (25–50 µg) if mildly symptomatic, elderly, or cardiac disease.

— Take fasting, 30–60 min before breakfast, separated from calcium, iron, PPIs, and bile acid sequestrants by ≥4 h.

— Pregnancy or attempting conception: target TSH <2.5 mIU/L in first trimester, <3.0 thereafter.

— Breastfeeding: full replacement is safe and encouraged to maintain milk supply and infant cognition.

— Recheck TSH 6 weeks after initiation or dose change.

— No antithyroid drugs (methimazole, PTU) in PPT — destructive disease.

— No radioiodine ablation during lactation; defer or use alternative if Graves later confirmed.

— NSAIDs unnecessary (no pain); reserve for subacute granulomatous thyroiditis.

— Selenium supplementation: not recommended outside research settings.

Board pearl: Treat symptoms in the thyrotoxic phase (β-blocker) and hormone deficiency in the hypothyroid phase (levothyroxine) — never methimazole. Re-evaluate need for levothyroxine at 6–12 months unless pregnant or conceiving.

Thyrotoxic phase — β-blockers:

Hypothyroid phase — levothyroxine:

Adjuncts and what to avoid:

Expanded Pharmacology and Treatment Nuances

— Propranolol preferred for short-term symptomatic control; 2–3 mg/kg/day infant exposure via milk is negligible.

— Metoprolol acceptable; labetalol if comorbid hypertension or preeclampsia carryover.

— Avoid atenolol and nadolol — higher milk transfer, reports of neonatal bradycardia.

— Use brand-consistent product or consistent generic; bioavailability varies.

— Liquid or soft-gel formulations may bypass absorption issues (PPIs, celiac, bariatric surgery).

— Iron and prenatal vitamins are common postpartum — counsel on 4-hour separation.

— In overt hypothyroid PPT trying to conceive: increase dose by ~30% (two extra tablets/week) as soon as pregnancy confirmed and notify obstetrics.

— When TSH rises above normal after thyrotoxic phase, stop β-blocker and reassess for hypothyroid symptoms.

— If TSH 5–10 and asymptomatic, recheck in 4–6 weeks before committing to levothyroxine.

— After 6–12 months on stable dose, halve the dose and recheck TSH in 6 weeks; if still normal, discontinue and recheck in another 6 weeks.

— Do not taper during active pregnancy or attempts at conception.

— Estrogen-containing contraceptives ↑ TBG → may need higher levothyroxine dose.

— Sertraline, rifampin, phenytoin, carbamazepine ↑ levothyroxine clearance.

— Calcium carbonate, ferrous sulfate, sucralfate, cholestyramine ↓ absorption.

— "Your immune system is rebalancing after pregnancy and temporarily attacking the thyroid; most women recover within a year, but we will watch you closely."

CCS pearl: In a CCS case, order TSH, free T4, TPO, TRAb on day 1, start propranolol for thyrotoxic symptoms, schedule office follow-up in 4–6 weeks with repeat TSH, and document PHQ-9 to co-screen postpartum depression.

Choosing the right β-blocker postpartum:

Levothyroxine pearls:

Managing the transition between phases:

Tapering levothyroxine after recovery:

Drug interactions worth flagging:

Patient counseling scripts:

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of preexisting hypertension, gestational diabetes, and subclinical cardiovascular disease.

— Thyrotoxic phase poses greater risk of atrial fibrillation — obtain baseline ECG if HR persistently >100 or palpitations are prominent.

— Initiate β-blocker at lower doses (e.g., propranolol 10 mg TID, metoprolol 12.5–25 mg BID) and titrate.

— Levothyroxine: start low (25–50 µg/day) and titrate to avoid precipitating angina or arrhythmia, especially if known CAD.

— Thyroid hormone metabolism minimally affected by CKD, but TSH may be mildly elevated at baseline in advanced CKD — interpret cautiously.

— Metoprolol and propranolol: hepatically metabolized, no renal dose adjustment needed.

— Atenolol and nadolol: renally cleared — additional reason to avoid postpartum.

— Levothyroxine: no renal adjustment; monitor TSH every 6 weeks as usual.

— Propranolol and metoprolol undergo extensive hepatic metabolism — start at half-dose in cirrhosis.

— Consider atenolol despite lactation concerns if hepatic dysfunction is severe and patient is not breastfeeding.

— Levothyroxine absorption may be reduced in cholestatic disease; monitor TSH more frequently.

— Type 1 DM: PPT risk 3-fold; screen TSH at 6–8 weeks and 6 months postpartum even if asymptomatic.

— Celiac, vitiligo, pernicious anemia, APS-2: same screening logic.

— Levothyroxine absorption can be erratic with active celiac — confirm dietary adherence.

Step 3 management: In any postpartum woman ≥35 with thyrotoxic palpitations, obtain a baseline ECG, screen for AF, and start a β-blocker that is breastfeeding-compatible and hepatic/renal-appropriate — propranolol or metoprolol are usually correct.

Applicability: PPT by definition occurs in women within 12 months of pregnancy, so true geriatric cases are rare; however, advanced maternal age (≥35) is increasingly common and warrants extra attention to cardiovascular and metabolic comorbidities.

Older postpartum women (≥35–40):

Renal impairment:

Hepatic impairment:

Comorbid autoimmune disease:

Special Populations — Pregnancy, Lactation, and Subsequent Pregnancies

— Routine universal screening is not recommended by ACOG/USPSTF — targeted screening only.

— Screen TSH and TPO antibodies in women with type 1 DM, prior PPT, recurrent miscarriage, infertility, or autoimmune disease history.

— TPO-positive in first trimester → ~50% risk of PPT; counsel proactively and plan postpartum TSH at 6–12 weeks, 6 months, and 12 months.

— Breastfeeding is encouraged in both phases of PPT.

— β-blockers: prefer propranolol or metoprolol (low milk transfer); avoid atenolol/nadolol.

— Levothyroxine: physiologic, safe and beneficial; supports milk supply.

— Radioiodine: contraindicated; if absolutely needed for Graves diagnosis, must wean before scanning.

— Iodinated contrast: avoid unless essential; transient infant TSH elevation possible.

— Recurrence ~70% — counsel before next conception.

— Check TSH preconception, each trimester, and at 6–12 weeks postpartum.

— Women on levothyroxine for prior PPT-induced permanent hypothyroidism: increase dose ~30% as soon as pregnancy confirmed.

— Hypothyroid phase mimics PPD; always check TSH in any postpartum woman screening positive on PHQ-9 or Edinburgh ≥10.

— Treating undiagnosed hypothyroidism may resolve mood symptoms and improve SSRI response.

— Estrogen-containing methods raise TBG and may require levothyroxine dose increase.

Board pearl: A woman with TPO antibodies in the first trimester has a coin-flip risk of PPT — schedule TSH at 6–8 weeks and 6 months postpartum prospectively, and counsel about 70% recurrence in future pregnancies.

Definitional clarification: PPT occurs after delivery, but pregnancy intersects in three crucial ways: antenatal risk prediction, postpartum lactation considerations, and recurrence in future pregnancies.

Antenatal prediction:

Lactation considerations:

Subsequent pregnancies:

Postpartum depression overlap:

Contraception:

Complications and Adverse Outcomes

— Most common and consequential pitfall; untreated hypothyroidism prolongs fatigue, cognitive impairment, and depressive symptoms, impairing maternal–infant bonding and breastfeeding.

— Occurs in 20–40% within 5–10 years, even after apparent recovery.

— Risk factors: high TPO titer, severe initial hypothyroid phase, multiparity, hypoechoic thyroid on ultrasound, age >35, smoking.

— Mandates annual lifelong TSH screening.

— Both untreated hyperthyroidism (catabolic state) and hypothyroidism (prolactin dysregulation) reduce milk supply.

— Often reversible with euthyroid restoration.

— Atrial fibrillation, especially in older women or those with preexisting cardiac disease.

— Pericardial effusion in profound hypothyroidism (rare).

— Untreated overt hypothyroidism: miscarriage, preterm delivery, preeclampsia, low birth weight, impaired neurodevelopment.

— Untreated overt hyperthyroidism in a future pregnancy (if PPT was actually Graves): fetal goiter, prematurity, IUGR.

— Inappropriate methimazole in PPT thyrotoxicosis → iatrogenic hypothyroidism, agranulocytosis, hepatotoxicity.

— Inappropriate radioiodine ablation in PPT → permanent hypothyroidism for a self-limited disease, plus disruption of lactation.

— Overtreatment with levothyroxine → iatrogenic thyrotoxicosis, osteoporosis, AF.

— Anxiety, panic-like symptoms during thyrotoxic phase, often persisting until diagnosis is made and validated.

Key distinction: The biggest "complication" tested on Step 3 is misdiagnosis: labeling thyrotoxic-phase PPT as anxiety or hypothyroid-phase PPT as postpartum depression — both can be excluded with a single TSH.

Misdiagnosis as postpartum depression:

Persistent (permanent) hypothyroidism:

Lactation failure:

Cardiac:

Obstetric in subsequent pregnancies:

Iatrogenic harms:

Psychological:

When to Escalate Care — Consults and Inpatient Triage

— Diagnostic uncertainty between PPT and Graves (e.g., ambiguous TRAb, persistent thyrotoxicosis >2–3 months, large goiter, ophthalmopathy).

— Severe symptoms unresponsive to β-blockers.

— Pregnancy in a woman with prior PPT and current thyroid dysfunction.

— Recurrent or refractory hypothyroid phase, especially if planning more pregnancies.

— Suspicious nodule on examination or ultrasound.

— New atrial fibrillation, sustained tachyarrhythmia, or symptomatic bradycardia.

— Underlying CAD or cardiomyopathy.

— PHQ-9 ≥15, suicidal ideation, psychotic features, or postpartum psychosis — emergent.

— Persistent depression despite euthyroid restoration.

— Thyroid storm (much more likely Graves than PPT): fever, HR >140, AMS, GI symptoms, heart failure → ICU; β-blocker, PTU/methimazole, iodine, glucocorticoids, supportive care.

— Myxedema coma: hypothermia, hypotension, bradycardia, hyponatremia, altered mentation → ICU; IV levothyroxine ± T3, stress-dose hydrocortisone before thyroid hormone (to avoid adrenal crisis), passive rewarming.

— New-onset AF with hemodynamic instability → telemetry/ICU.

— Hemodynamic stability, symptom control, established outpatient endocrine and OB-GYN follow-up within 1–2 weeks, medication reconciliation, breastfeeding plan addressed.

CCS pearl: A postpartum woman with HR 140, fever, agitation, and FT4 markedly elevated → move location to ICU, order β-blocker, methimazole, iodine (1 h after methimazole), hydrocortisone, and consult endocrinology — and reconsider whether the diagnosis is actually Graves rather than PPT.

Most PPT is managed outpatient by the primary care physician or OB-GYN. Escalation is needed in specific scenarios.

Endocrinology referral:

Cardiology referral:

Psychiatry/behavioral health:

Inpatient triage — rare but high-yield emergencies:

Discharge readiness criteria after hospitalization:

Key Differentials — Other Thyroid Conditions

— Persistent hyperthyroidism, ophthalmopathy, pretibial myxedema, diffuse bruit, positive TRAb/TSI, high RAIU, high T3:T4 ratio.

— May coexist with or follow pregnancy; often worsens postpartum due to immune rebound.

— Distinguish because treatment differs — antithyroid drugs ± definitive therapy.

— Older women, focal nodule(s), focal uptake on scan, TRAb negative.

— Painful, tender thyroid, post-viral, elevated ESR/CRP, low RAIU.

— Treated with NSAIDs ± prednisone; not related to pregnancy timing.

— Same antibody profile (TPO+) as PPT and may overlap; distinction is temporal — Hashimoto is chronic and not triphasic.

— Many women with "permanent hypothyroidism after PPT" actually have unmasked Hashimoto.

— Same destructive pathology as PPT but not temporally linked to pregnancy.

— Amiodarone (both hypo- and hyperthyroidism), lithium, interferon-α, immune checkpoint inhibitors, tyrosine kinase inhibitors.

— Recent iodinated contrast, amiodarone, kelp.

— Ectopic thyroid hormone production or hCG-mediated TSH receptor stimulation.

Key distinction: Among thyroid mimics, Graves vs. PPT is the single most tested decision. TRAb positive + high RAIU + ophthalmopathy = Graves; TPO positive + low RAIU + transient course = PPT.

Graves disease (most important mimic):

Toxic adenoma / toxic multinodular goiter:

Subacute granulomatous (De Quervain) thyroiditis:

Hashimoto thyroiditis (chronic lymphocytic):

Silent (painless) thyroiditis:

Drug-induced thyroid dysfunction:

Iodine-induced (Jod-Basedow or Wolff-Chaikoff):

Struma ovarii / gestational trophoblastic disease (rare):

Key Differentials — Non-Thyroid Postpartum Mimics

— Overlaps profoundly with hypothyroid phase: fatigue, anhedonia, poor concentration, weight changes, sleep disturbance.

— Always check TSH in any postpartum woman with PHQ-9 ≥10 or Edinburgh ≥10.

— Treat both: SSRI plus levothyroxine if indicated.

— Palpitations, tremor, insomnia, irritability — mirrors thyrotoxic phase.

— TSH and free T4 differentiate; absence of weight loss and tremor favors anxiety.

— Hallucinations, delusions, disorganized behavior, often within first 2 weeks — psychiatric emergency requiring hospitalization. Not PPT.

— Severe peripartum hemorrhage → failure to lactate, amenorrhea, fatigue, hypotension, hyponatremia.

— Central hypothyroidism: low TSH and low free T4 — opposite of PPT hypothyroid phase.

— Look for low cortisol, prolactin, gonadotropins.

— Autoimmune pituitary inflammation, often peripartum; central hypothyroidism plus headache and visual changes.

— Dyspnea, edema, palpitations — can mimic thyrotoxic symptoms; echo and BNP differentiate.

— Fatigue, tachycardia, pallor — check CBC and ferritin.

— Diagnosis of exclusion after TSH and depression screen.

— Suppressed TSH with low thyroglobulin suggests exogenous T4.

Board pearl: Sheehan syndrome has low TSH + low free T4 (central pattern); PPT hypothyroid phase has high TSH + low free T4 (primary pattern). The TSH direction is the single discriminator.

Postpartum depression (PPD):

Postpartum anxiety / panic disorder:

Postpartum psychosis (emergency):

Sheehan syndrome (postpartum pituitary necrosis):

Lymphocytic hypophysitis:

Postpartum cardiomyopathy:

Anemia (iron deficiency, blood loss):

Sleep deprivation, normal puerperium:

Substance use, especially stimulant or thyroid-supplement misuse:

Secondary Prevention, Discharge Planning, and Long-Term Strategy

— Annual TSH for life — 20–40% develop permanent hypothyroidism within a decade.

— Counsel on symptoms of hypothyroidism to prompt earlier testing.

— Lifelong levothyroxine, target TSH 0.5–2.5 (lower if planning pregnancy).

— Educate on consistent timing, drug interactions, and the need to increase dose by ~30% in pregnancy.

— Preconception TSH; target <2.5 mIU/L before conception in women with known thyroid disease.

— Document prior PPT in problem list — drives postpartum screening at 6–8 weeks, 6 months, 12 months.

— Recurrence rate ~70% — explicit counseling.

— Smoking cessation (smoking worsens autoimmune thyroid disease and Graves ophthalmopathy).

— Avoid excess iodine (kelp, high-dose supplements).

— Adequate selenium and iodine intake from balanced diet; no role for high-dose selenium outside research.

— β-blocker with taper plan if in thyrotoxic phase.

— Levothyroxine with prescribed dose, timing instructions, and 6-week TSH recheck.

— SSRI if PPD coexists.

— Iron/prenatal vitamins separated by ≥4 h from levothyroxine.

— Avoid over-replacement (suppressed TSH increases AF and osteoporosis risk).

— DEXA not routinely indicated but consider in women with persistent suppression.

Step 3 management: After PPT resolves, annual TSH is the single most important long-term action; in any future pregnancy, check TSH preconception and again at 6–8 weeks postpartum to catch recurrence early.

After resolution of PPT (return to euthyroid):

If permanent hypothyroidism develops:

Subsequent pregnancy planning:

Lifestyle and modifiable risks:

Discharge medication list (if hospitalized for severe symptoms):

Bone and cardiovascular health:

Follow-Up, Monitoring Parameters, and Counseling

— Thyrotoxic phase: TSH and free T4 every 4–8 weeks until normalization, then every 2 months until hypothyroid phase is excluded.

— Hypothyroid phase on observation: TSH every 6–8 weeks.

— Hypothyroid phase on levothyroxine: TSH 6 weeks after each dose change; once stable, every 3 months for the first year.

— After recovery: TSH at 6 and 12 months, then annually for life.

— Track weight, resting HR, mood, sleep, energy, lactation volume.

— Encourage early call for new palpitations, AF symptoms, severe fatigue, or worsening depression.

— 4–6 weeks after diagnosis to reassess symptoms and labs.

— Routine postpartum visit at 6 weeks (already standard) — incorporate TSH if not done.

— 6-month and 12-month visits to assess phase transition or resolution.

— Lactation consultant referral if supply drops during either phase.

— Reassure on safety of propranolol/metoprolol and levothyroxine.

— Natural history: ~80% recover by 12–18 months; 20–40% develop permanent hypothyroidism.

— Recurrence ~70% in future pregnancies; plan early TSH screening.

— Annual lifelong TSH; symptom-prompted earlier testing.

— Distinguish thyroid symptoms from postpartum mood disorder — both can coexist and both should be treated.

— Add "postpartum thyroiditis" to problem list to ensure portability if patient changes providers.

CCS pearl: In a CCS case, schedule office follow-up at 4–6 weeks, repeat TSH/FT4, PHQ-9, and patient education on recurrence and lifelong annual TSH — these specific actions are commonly required to score full points.

Monitoring cadence by phase:

Symptom diary and patient self-monitoring:

Office visits:

Breastfeeding support:

Counseling content:

Documentation:

Ethical, Legal, and Patient Safety Considerations

— Anchoring bias is the central safety issue — postpartum mood and fatigue symptoms are often attributed solely to PPD or "normal new-mother exhaustion." The standard of care is to check TSH in any symptomatic postpartum woman.

— Document negative or positive screening to protect against missed diagnosis claims.

— Radioactive iodine uptake/scan in a breastfeeding woman requires explicit informed consent regarding temporary or permanent cessation of breastfeeding for that infant; offer Doppler ultrasound as the lactation-preserving alternative.

— Antithyroid drugs would be inappropriate for PPT; prescribing them in error is both a clinical and consent issue — patients consented to treatment of a condition they do not have.

— Obstetric care frequently ends at the 6-week visit. Without explicit hand-off, PPT diagnosed at 4–6 months may be missed.

— Closed-loop communication between OB-GYN, primary care, and endocrinology, and clear documentation in the problem list, prevents fragmentation.

— At hospital discharge or OB sign-off, name the responsible clinician for ongoing thyroid monitoring.

— Screen for postpartum depression and intimate partner violence at every visit; positive PHQ-9 with suicidal or infanticidal ideation triggers urgent psychiatric evaluation regardless of thyroid status.

— Black and Hispanic women have lower postpartum follow-up rates in the US; proactive outreach and home BP/symptom monitoring programs reduce disparity in PPT detection.

— Lifelong levothyroxine after a single hypothyroid phase, without confirmatory off-treatment testing, is overtreatment and risks iatrogenic thyrotoxicosis, AF, and osteoporosis — attempt a taper at 6–12 months unless contraindicated.

Step 3 management: Before ordering RAIU in a postpartum woman, document lactation status, counsel on breastfeeding interruption, and offer Doppler ultrasound as an alternative — this is both an ethical and a safety standard.

Diagnostic safety:

Informed consent edge cases:

Transition-of-care risk:

Mandatory reporting and safety:

Health equity:

Avoiding overtreatment:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: If a postpartum woman has palpitations + suppressed TSH + low RAIU + negative TRAb, the answer is β-blocker and observe — never antithyroid drugs and never radioiodine ablation.

Prevalence: 5–10% of US postpartum women; up to 25% with type 1 DM.

Antibody: TPO positive in 60–85%; high first-trimester TPO predicts ~50% PPT risk.

Triphasic pattern: thyrotoxic 1–6 months → hypothyroid 3–12 months → euthyroid 12–18 months (only ~25%; remainder isolated phases).

T4:T3 ratio high in PPT (destructive release of stored hormone); T3:T4 ratio high in Graves.

RAIU: Low (<5%) in PPT; high and diffuse in Graves.

Ultrasound Doppler: Decreased vascularity in PPT; "thyroid inferno" in Graves.

TRAb: Negative in PPT, positive in Graves.

ESR/CRP: Normal in PPT; elevated in subacute granulomatous thyroiditis.

Treatment thyrotoxic phase: β-blocker (propranolol/metoprolol); no methimazole, no RAI.

Treatment hypothyroid phase: Levothyroxine if symptomatic, TSH >10, breastfeeding, or pregnant/trying.

Lactation-safe β-blockers: Propranolol, metoprolol. Avoid atenolol/nadolol.

Recurrence in next pregnancy: ~70%.

Permanent hypothyroidism: 20–40% within 5–10 years → annual TSH for life.

Sheehan syndrome: Low TSH + low free T4 (central); contrast with PPT high TSH + low free T4 (primary).

Pregnancy TSH targets: <2.5 first trimester, <3.0 thereafter.

Levothyroxine timing: Fasting, 30–60 min before food; separate iron/calcium by 4 hours.

Postpartum depression overlap: Always check TSH if PHQ-9 ≥10 or Edinburgh ≥10.

Universal screening: Not recommended; targeted screening in high-risk women (type 1 DM, prior PPT, TPO+, autoimmune disease).

Goiter character: Small, firm, painless, nontender, no bruit — opposite of Graves.

Board Question Stem Patterns

— 28-year-old woman 3 months postpartum, palpitations and weight loss, suppressed TSH; symptoms resolve, but at 7 months has fatigue and TSH 22.

— Diagnosis: PPT. Next step: levothyroxine if symptomatic or TSH >10.

— Postpartum thyrotoxicosis with proptosis and diffuse bruit, positive TRAb.

— Answer: Graves disease — start methimazole (or PTU first trimester if pregnant); not PPT.

— Postpartum woman with suppressed TSH and mild palpitations; asks about methimazole.

— Correct: Propranolol; methimazole inappropriate in destructive thyroiditis.

— Diagnostic uncertainty postpartum, patient breastfeeding.

— Best next test: Doppler ultrasound, not RAIU (or wean before RAIU with explicit consent).

— 5-month postpartum woman with fatigue, low mood, poor concentration, weight gain, PHQ-9 14.

— Next step: TSH before assuming pure PPD; treat both if hypothyroid.

— Patient with prior PPT now planning pregnancy — counsel on 70% recurrence, preconception TSH <2.5.

— Patient recovered from PPT 2 years ago — next step is annual TSH indefinitely.

— Postpartum hemorrhage, failure to lactate, fatigue, low TSH and low free T4 → Sheehan, not PPT.

— Type 1 diabetic 8 weeks postpartum with fatigue — high pretest probability of PPT; screen TSH.

— Patient on levothyroxine 12 months postpartum, asymptomatic, TSH 0.2 — taper and recheck, not continue indefinitely without confirming need.

Key distinction: Always anchor the question to timing relative to delivery (≤12 months), TRAb status, and RAIU/Doppler vascularity — these three data points resolve nearly every PPT vignette.

"Thyrotoxic-then-hypothyroid" stem:

"Differentiate from Graves" stem:

"Wrong drug" trap:

"Imaging in lactation" stem:

"PPD vs hypothyroidism" stem:

"Recurrence in next pregnancy" stem:

"Annual screening" stem:

"Sheehan vs PPT" stem:

"Type 1 DM postpartum" stem:

"Overtreatment" trap:

One-Line Recap

Postpartum thyroiditis is a transient, autoimmune, destructive thyroiditis occurring within 12 months of pregnancy that classically follows a triphasic thyrotoxic-then-hypothyroid-then-euthyroid course, is distinguished from Graves disease by low radioiodine uptake and negative TRAb, and is managed symptomatically with β-blockers in the thyrotoxic phase and levothyroxine in the hypothyroid phase — never with antithyroid drugs or radioiodine ablation.

Board pearl: The single highest-yield reflex on Step 3 — when a postpartum woman has any new mood, energy, weight, or cardiac symptom within 12 months of delivery, order a TSH first, then let TRAb and RAIU (or Doppler) settle PPT versus Graves before choosing therapy.

Recognition: Any postpartum woman (≤12 months) with new palpitations, weight loss, fatigue, depression, or impaired lactation deserves a TSH — and a PHQ-9, because postpartum depression and PPT frequently coexist and the hypothyroid phase is the most commonly missed endocrine diagnosis of the puerperium.

Diagnosis: TPO positive, TRAb negative, low RAIU, decreased Doppler vascularity, small painless nontender goiter — collectively separate PPT from Graves, subacute granulomatous thyroiditis, and Sheehan syndrome (which shows central low TSH/low FT4).

Treatment: Propranolol or metoprolol (lactation-safe) for thyrotoxic symptoms; levothyroxine when symptomatic, TSH >10, breastfeeding, or planning/achieving pregnancy — with attempt at taper at 6–12 months unless pregnant.

Long term: Counsel on ~70% recurrence in subsequent pregnancies and 20–40% lifetime risk of permanent hypothyroidism, mandating annual TSH for life, preconception TSH <2.5, and a 30% levothyroxine dose increase as soon as a future pregnancy is confirmed.